US 12,409,178 B2
Methods and compositions comprising a KRasG12C inhibitor and a VEGF inhibitor for treating solid tumors
Marie Evangelista, San Francisco, CA (US); Mark Andrew Merchant, Redwood City, CA (US); Jennifer Lee Schutzman, Belmont, CA (US); Ting-Kun Mark Lin, Mill Valley, CA (US); Stephanie Royer Joo, San Diego, CA (US); Sandhya Vinayak Mandlekar, Foster City, CA (US); and Stuart G. Lutzker, Walnut Creek, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on May 14, 2024, as Appl. No. 18/663,549.
Application 18/663,549 is a continuation of application No. 17/524,050, filed on Nov. 11, 2021, granted, now 12,016,862.
Claims priority of provisional application 63/113,609, filed on Nov. 13, 2020.
Prior Publication US 2024/0299392 A1, Sep. 12, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/517 (2006.01); A61P 35/00 (2006.01); C07K 16/22 (2006.01)
CPC A61K 31/517 (2013.01) [A61P 35/00 (2018.01); C07K 16/22 (2013.01)] 19 Claims
 
1. A method of treating colorectal cancer (CRC) mediated by a KRasG12C mutation in a patient having CRC, the method comprising administering:

OG Complex Work Unit Chemistry
or an adipate salt thereof QD at an effective amount of about 50 mg-500 mg QD on days 1-21 of a first 21-day cycle; and
(b) an effective amount of bevacizumab Q3W on day 1 of the first 21-day cycle.